RU2017141447A - Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 - Google Patents

Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 Download PDF

Info

Publication number
RU2017141447A
RU2017141447A RU2017141447A RU2017141447A RU2017141447A RU 2017141447 A RU2017141447 A RU 2017141447A RU 2017141447 A RU2017141447 A RU 2017141447A RU 2017141447 A RU2017141447 A RU 2017141447A RU 2017141447 A RU2017141447 A RU 2017141447A
Authority
RU
Russia
Prior art keywords
influenza virus
virus
polypeptide
vlp
immune response
Prior art date
Application number
RU2017141447A
Other languages
English (en)
Russian (ru)
Inventor
Тед М. РОСС
Кори Дж. КРЕВАР
Дональд М. КАРТЕР
Original Assignee
Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн filed Critical Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн
Publication of RU2017141447A publication Critical patent/RU2017141447A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2017141447A 2012-03-30 2013-03-12 Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 RU2017141447A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261617815P 2012-03-30 2012-03-30
US61/617,815 2012-03-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014142785A Division RU2639551C2 (ru) 2012-03-30 2013-03-12 Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1

Publications (1)

Publication Number Publication Date
RU2017141447A true RU2017141447A (ru) 2019-02-13

Family

ID=49261015

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017141447A RU2017141447A (ru) 2012-03-30 2013-03-12 Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1
RU2014142785A RU2639551C2 (ru) 2012-03-30 2013-03-12 Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014142785A RU2639551C2 (ru) 2012-03-30 2013-03-12 Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1

Country Status (15)

Country Link
US (2) US9212207B2 (enExample)
EP (1) EP2831094B1 (enExample)
JP (1) JP2015513902A (enExample)
KR (1) KR20150004800A (enExample)
CN (1) CN104395336B (enExample)
AU (1) AU2013240365B2 (enExample)
BR (1) BR112014023900A2 (enExample)
CA (1) CA2868330A1 (enExample)
HK (1) HK1203522A1 (enExample)
IN (1) IN2014DN07399A (enExample)
MX (1) MX345150B (enExample)
MY (1) MY166953A (enExample)
RU (2) RU2017141447A (enExample)
SG (1) SG11201406153XA (enExample)
WO (1) WO2013148164A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2834969C1 (ru) * 2020-05-08 2025-02-19 Академиа Синика Химерные вакцины против гриппа

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883171B2 (en) * 2010-09-14 2014-11-11 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
JP6113155B2 (ja) 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
SG11201503989PA (en) * 2012-11-27 2015-06-29 Univ Pittsburgh Computationally optimized broadly reactive antigens for h1n1 influenza
US20140286981A1 (en) 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
JP6764408B2 (ja) * 2014-12-19 2020-09-30 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与
EP3233117A4 (en) * 2014-12-19 2018-05-16 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza
US10584148B2 (en) 2015-06-02 2020-03-10 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
US10927151B2 (en) * 2015-06-09 2021-02-23 Sanofi Pasteur Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US20200237898A1 (en) * 2015-09-21 2020-07-30 Oregon Health & Science University Vaccines intelligently produced by epitope recombination (viper) for influenza
EP3464328A1 (en) * 2016-06-02 2019-04-10 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
EP3464327A1 (en) 2016-06-03 2019-04-10 Sanofi Pasteur Inc. Modification of engineered influenza hemagglutinin polypeptides
US12521430B2 (en) 2018-03-28 2026-01-13 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising neuraminidase
EP3774884B1 (en) * 2018-03-28 2023-12-06 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising hemagglutinin
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
JP2021519600A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性インフルエンザ−フェリチンポリペプチド
US12098166B2 (en) 2018-11-06 2024-09-24 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition against avian influenza virus H5 subtype

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1294892T3 (da) 2000-06-23 2008-01-28 Wyeth Corp Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7566454B2 (en) 2005-02-24 2009-07-28 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
CA2615658A1 (en) 2005-07-19 2007-01-25 Dow Global Technolgies Inc. Recombinant flu vaccines
US20090327170A1 (en) 2005-12-19 2009-12-31 Claudio Donati Methods of Clustering Gene and Protein Sequences
US20080045472A1 (en) 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008091657A1 (en) * 2007-01-23 2008-07-31 Academia Sinica Flu vaccines and methods of use thereof
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
KR101255419B1 (ko) 2007-11-12 2013-04-17 이노비오 파마수티컬즈, 인크. 인플루엔자 바이러스의 다중 아형에 대한 신규 백신
SG187500A1 (en) 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
US7981428B2 (en) * 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
WO2010036970A2 (en) 2008-09-25 2010-04-01 Fraunhofer Usa, Inc. Influenza vaccines, antigens, compositions, and methods
US20110177122A1 (en) * 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
CN103585643A (zh) 2009-04-03 2014-02-19 梅里亚有限公司 运载新城疫病毒的禽疫苗
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US8883171B2 (en) 2010-09-14 2014-11-11 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
JP6113155B2 (ja) * 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
US9234008B2 (en) * 2012-02-07 2016-01-12 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
US9566327B2 (en) 2012-02-13 2017-02-14 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for human and avian H5N1 influenza
SG11201503989PA (en) 2012-11-27 2015-06-29 Univ Pittsburgh Computationally optimized broadly reactive antigens for h1n1 influenza

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2834969C1 (ru) * 2020-05-08 2025-02-19 Академиа Синика Химерные вакцины против гриппа
RU2855931C1 (ru) * 2020-05-08 2026-02-05 Академиа Синика Химерные вакцины против гриппа

Also Published As

Publication number Publication date
EP2831094B1 (en) 2018-06-13
KR20150004800A (ko) 2015-01-13
US20160279226A1 (en) 2016-09-29
CN104395336A (zh) 2015-03-04
BR112014023900A2 (pt) 2020-11-24
US20150017196A1 (en) 2015-01-15
IN2014DN07399A (enExample) 2015-04-24
MY166953A (en) 2018-07-25
CN104395336B (zh) 2018-01-23
MX2014011387A (es) 2014-10-14
US9212207B2 (en) 2015-12-15
MX345150B (es) 2017-01-18
HK1203522A1 (en) 2015-10-30
AU2013240365A1 (en) 2014-10-23
EP2831094A4 (en) 2015-10-14
US9555095B2 (en) 2017-01-31
CA2868330A1 (en) 2013-10-03
RU2014142785A (ru) 2016-05-20
WO2013148164A1 (en) 2013-10-03
EP2831094A1 (en) 2015-02-04
JP2015513902A (ja) 2015-05-18
RU2639551C2 (ru) 2017-12-21
SG11201406153XA (en) 2014-10-30
AU2013240365B2 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
RU2018113521A (ru) Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b
RU2014101401A (ru) Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств
RU2014142785A (ru) Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
JP2015506705A5 (enExample)
JP6679475B2 (ja) 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
AU2021232702B2 (en) Stabilized pre-fusion RSV F proteins
RU2015124805A (ru) Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вируса гриппа h1n1
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
TW201520221A (zh) 穩定化可溶性融合前ｒｓｖ ｆ多肽
CN103547676A (zh) 颗粒形式的免疫原性组合物和用于产生其的方法
RS61456B1 (sr) Stabilizovani rastvorljivi pre-fuzioni rsv f protein za primenu u profilaksi rsv infekcije
CA2811103A1 (en) Computationally optimized broadly reactive antigens for influenza
JP2016505538A5 (enExample)
WO2017207477A1 (en) Stabilized pre-fusion rsv f proteins
JP2014519817A5 (enExample)
US9896484B2 (en) Influenza virus recombinant proteins
JP2023539356A5 (enExample)
EP2773674A1 (en) Immunologic constructs and methods
CN101899461A (zh) 一种编码甲型流感病毒NP蛋白和M2e多肽的融合基因
CN118725052A (zh) 具有稳定融合前构象的呼吸道合胞病毒f蛋白
CA3213403A1 (en) Modified chimeric coronavirus spike protein for enhancement of viral titers
CN117045781A (zh) 一种基于分子佐剂的广谱型h9亚型禽流感ha亚单位黏膜疫苗及其制备方法和应用
CN109821014A (zh) 一种多抗原仿生流感疫苗及其制备方法和应用
OA19273A (en) Stabilized pre-fusion RSV F proteins.

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20201130